Holen Sie sich die Stockscreener-App
2.53
1.16%
-0.06
Schlusskurs vom Vortag:
$2.59
Offen:
$2.59
24-Stunden-Volumen:
3,865
Relative Volume:
0.19
Marktkapitalisierung:
$12.39M
Einnahmen:
$1.41M
Nettoeinkommen (Verlust:
$-9.84M
KGV:
-1.1818
EPS:
-2.1408
Netto-Cashflow:
$-7.85M
1W Leistung:
-6.57%
1M Leistung:
-5.54%
6M Leistung:
-3.03%
1J Leistung:
-29.86%
1-Tages-Spanne:
$2.53
$2.59
1-Wochen-Bereich:
$2.53
$2.78
52-Wochen-Spanne:
$2.15
$4.56
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
Firmenname
Bioline Rx Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare BLRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
2.555 | 12.56M | 1.41M | -9.84M | -7.85M | -2.1408 |
VRTX
Vertex Pharmaceuticals Inc
|
522.72 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.34 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,003.96 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.64 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.05 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2017-05-18 | Hochstufung | Maxim Group | Hold → Buy |
| 2017-02-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-08-17 | Bestätigt | Maxim Group | Buy |
| 2015-07-27 | Bestätigt | ROTH Capital | Buy |
| 2015-06-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Bioline Rx Ltd Adr Aktie (BLRX) Neueste Nachrichten
YP2 Stock Price and Chart — HAM:YP2 - TradingView
BioLineRx Earnings Call Highlights GLIX1 Momentum - TipRanks
BioLineRx (NASDAQ: BLRX) Announces $3.3M Net Raise via 480,696 ADSs at $2.78 Each - Kalkine Media
BioLineRx Raises $3.75 Million in August Registered Direct Offering and Warrant Deal - TipRanks
Earnings call transcript: BioLineRx Q2 2026 revenue flat as GLIX1 advances - Investing.com
BioLineRx Advances GLIX1 Oncology Program and Posts Q2 2026 Results - TipRanks
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement - Sahm
BioLineRx stock falls on $3.75M share offering plan - Investing.com India
BioLineRx Raises $3.75 Million in Registered Direct Offering, Retires ATM Facility - TipRanks
BioLineRx raises $3.75 million in registered direct offering - Investing.com
What Could BioLineRx (NASDAQ:BLRX) Reveal as NASDAQ Eyes Results? - Kalkine Media
Why Are Nasdaq, S&P 500 Futures Falling Premarket? NVDA, SKHY, SPCX, TSLA, MRNA, MSTR, PURR, WMT Stocks In Focus - TradingView
BioLineRx Sets September 23, 2026 Shareholders Meeting to Boost Capital and Approve New Equity Awards - TipRanks
Serina Therapeutics: Buy Rating Reiterated, $11 Price Target Maintained on Strong SER-252 Clinical Progress - TipRanks
Analyst Justin Walsh Reiterates Buy on NeuroOne, Maintains $8 Target on Partner-Driven RF Ablation Growth and Pipeline Upside - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS) - The Globe and Mail
Analysts Offer Insights on NA Companies: Starz Entertainment Corp (STRZ), Bluelinx Holdings (BXC) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Price to sales forward of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
Price to earnings forward of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
BioLineRx, Hemispherian to present GLIX1 data at ESMO 2026 - Investing.com
Price to earnings forward of BioLineRX Ltd. Sponsored ADR – MUN:YP2 - TradingView
Enterprise value to revenue forward of BioLineRX Ltd. Sponsored ADR – MUN:YP2 - TradingView
BioLineRx reports preclinical data on GLIX1 with PARP inhibitor - Investing.com
BioLineRx and Hemispherian Report GLIX1–PARP Synergy in Ovarian Cancer Model, Plan Trial Expansion - TipRanks
India Celiac Disease Treatment Market Size & Outlook, 2033 - Grand View Research
YP2 Forecast — Price Target — Prediction for 2027 - TradingView
A41038 Forecast — Price Target — Prediction for 2027 - TradingView
BLRX Forecast — Price Target — Prediction for 2027 - TradingView
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), TScan Therapeutics (TCRX) and PACS Group Inc (PACS) - The Globe and Mail
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
BioLineRx Earnings Call: Pipeline Momentum, Profit Squeeze - The Globe and Mail
JonesTrading Reaffirms Their Buy Rating on Bioline RX Ltd Sponsored ADR (BLRX) - The Globe and Mail
BioLineRx shares rise 4% on first patient dosed in cancer trial - Investing.com
Earnings call transcript: BioLineRx’s Q1 2026 reveals mixed results By Investing.com - Investing.com South Africa
Earnings call transcript: BioLineRx’s Q1 2026 reveals mixed results - Investing.com
BioLineRx shares rise 4% on first patient dosed in cancer trial By Investing.com - Investing.com South Africa
BioLineRx Kicks Off GLIX1 Clinical Trial as Q1 2026 Loss Widens on Higher R&D Spend - TipRanks
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update - Barchart.com
BLRXBioline Rx Ltd ADR Stock Price and Quote - Finviz
BioLineRx and Hemispherian Showcase New GLIX1 Data Ahead of ASCO 2026 as First-in-Human GBM Trial Enrolls - TipRanks
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting - Barchart.com
BLRX Technical Analysis | Trend, Signals & Chart Patterns | BIOLINERX LTD-SPONS ADR (NASDAQ:BLRX) - ChartMill
BioLineRx to Report First Quarter 2026 Results on May 27, 2026 - Morningstar
BioLineRx and Hemispherian Report Strong Preclinical GLIX1 Data in Temozolomide-Resistant Glioblastoma - TipRanks
BioLineRx reports preclinical data for GBM treatment GLIX1 - Investing.com
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts - Barchart.com
Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI), Immunic (IMUX) and Protara Therapeutics (TARA) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Number of shareholders of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Definium Therapeutics (DFTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA) - The Globe and Mail
Finanzdaten der Bioline Rx Ltd Adr-Aktie (BLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):